Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 10/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196966 | 0.88 | CTSD (0.38) | CTSDCTSBCTSKF2TASP1 | |
| SCHEMBL29519856 | 0.84 | BACE1 (0.39) | CTSDKISS1RRENBACE1EDNRA | |
| SCHEMBL2183867 | 0.82 | OPRM1 (0.33) | CTSDKISS1RBACE1F2 | |
| SCHEMBL30536718 | 0.82 | ENPEP (0.39) | — | |
| SCHEMBL2194411 | 0.80 | OPRK1 (0.38) | — | |
| SCHEMBL2183047 | 0.80 | CTSC (0.35) | CTSDBACE1 | |
| SCHEMBL29881596 | 0.80 | BACE1 (0.46) | CTSDBACE1 | |
| SCHEMBL31471617 | 0.79 | BACE1 (0.45) | CTSDBACE1 | |
| SCHEMBL30006221 | 0.79 | MAGI3 (0.40) | CTSDKISS1RBACE1 | |
| SCHEMBL30434077 | 0.79 | CTSD (0.42) | CTSDRENBACE1EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CTSD 1192/4885KISS1R 1433/4885REN 2640/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CTSD 1192/4885KISS1R 1433/4885REN 2640/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | CTSD 912/4885KISS1R 1880/4885REN 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.